# Processa Pharmaceuticals

Processa Pharmaceuticals is an Asset Manager based in Hanover, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Hanover, United States
- **Region:** North America
- **Address:** Hanover, MD, United States
- **Founded:** 2011
- **Assets under management:** Undisclosed
- **Website:** processapharma.com
- **LinkedIn:** https://www.linkedin.com/company/processapharma

## Regulatory record

- **Reports private funds:** No

## About

Processa Pharmaceuticals incorporated in 2011 and reorganized through a reverse merger in 2021, taking the ticker PCSA on Nasdaq. George Ng has served as CEO since 2017, steering a lean operation that deliberately avoids broad pipelines in favor of two core programs. The firm's founding thesis targets the side-effect burden of existing chemotherapy agents, a problem oncologists manage daily but few drug developers prioritize. Strategy centers on Next Generation Capecitabine — partnered with a South Korean manufacturer — and PCS12852, a treatment for gastroparesis licensed from a Japanese originator. Both programs live in Phase 2, meaning all value sits in data readouts, not revenue. Processa does not operate as a fund or manage outside capital; it burns operating cash like every pre-revenue biotech, funding itself through periodic public-market raises. Team size remains small — SEC filings typically list under 10 named officers and directors — with R&D run by Dr. David Young. No significant physical footprint beyond the Hanover headquarters and no disclosed capital-deployment headcount. The firm does not disclose AUM; its last reported cash position was roughly $6 million as of early 2025. In March 2025: Announced a $2 million registered direct offering to extend its operational runway (per SEC filing, March 2025). Processa's structural differentiator is its inversion of the standard oncology-development model. Instead of chasing a novel target, it reformulates drugs with decades of human safety data — a strategy that cuts Phase 1 failure risk but demands a high-conviction bet on differentiated tolerability. Success depends entirely on whether a less-toxic version of an established agent can demonstrate meaningful improvement in a trial setting where the comparator is already widely available and generic.

## Sectors

- Healthcare Services
- Biotechnology

## People

- George Ng — Chief Executive Officer
- James Stanker — Chief Financial Officer
- David Young — President of Research and Development

## Questions

### Who runs investment decisions at Processa Pharmaceuticals?

Processa does not invest capital in the sense of a family office or fund manager. As a clinical-stage pharmaceutical company, resource-allocation decisions are operational calls made by CEO George Ng and the board of directors, primarily focused on advancing its two drug candidates through Phase 2 trials. The firm's burn rate dictates timing for any future equity raises, which are standard SEC-regulated public offerings rather than fund closes.

### What is Processa's known posture on co-investments alongside external parties?

The firm does not co-invest. When Processa raises capital, it does so through registered direct offerings or other SEC-compliant equity transactions available to accredited institutional investors on standard market terms. There is no co-investment club, SPV structure, or sidecar vehicle.

### How is Processa Pharmaceuticals related to its predecessor entity?

The current Processa Pharmaceuticals emerged from a 2021 reverse merger with an older corporate shell, which provided a faster path to a public listing. The merged entity retained the Processa name and clinical programs and has operated continuously as a clinical-stage firm since. CEO George Ng has led the organization since before the merger.

## Related profiles

- [Private Wealth Advisors VI](https://altss.com/profile/private-wealth-advisors-vi-llc)
- [ProConfirm](https://altss.com/profile/proconfirm)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/processa-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology